Eli Lilly and CompanyvsMaze Therapeutics

LLY and MAZE stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,382.75

Value $1.30T

-2.32%
LLY's page

MAZE

Maze Therapeutics, Inc.

$31.20

Value $1.7B

-5.08%
MAZE's page

Eli Lilly and Company (LLY) has a market value of $1.30T and Maze Therapeutics (MAZE) $1.7B. Over the last year, with dividends, LLY moved +36.2% and MAZE -6.9%. Dividend yield: LLY 0.46%, MAZE none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LLY$1.30T

    MAZE$1.7B

    LLY is 765 times MAZE

  • Revenue, 12 months

    LLY$86.5B

    MAZE–

  • Net income, 12 months

    LLY$27.6B

    MAZE-$151M

  • Operating margin

    LLY–

    MAZE–

  • ROIC

    LLY35.5%

    MAZE-31.8%

    67.3 points apart

  • P/E

    LLY47.3

    MAZE–

  • Dividend yield

    LLY0.5%

    MAZE0.0%

    0.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LLY+36.2%

MAZE-6.9%

75100125150DecFebAprJunAugOct
Returns by period
PeriodLLYWith dividendsMAZEWith dividends
1 year since November 17, 2025+36.2%Price +35.3%-6.9%Price -6.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LLYEli Lilly and CompanyMAZEMaze Therapeutics

Valuation

LLYMAZE
Valuation
Price$1,382.75$31.20
Market value$1.30T$1.7B
Enterprise value (EV)$1.35T$1.4B
P/E47.3–
P/E, 5-year median49.9–
P/B32.44.0
EV/EBIT38.8–
Free cash flow yield1.5%–

Results and growth

LLYMAZE
Results and growth
Revenue, 12 months$86.5B–
Net income, 12 months$27.6B-$151M
Free cash flow, 12 months$19.7B-$115M
Earnings per share, 12 months$30.81-$2.60
Revenue growth, year on year44.7%–
Revenue growth a year, past+21.6%over 5 years–
EPS growth a year, past+27.6%over 5 years–

Margins and returns on capital

LLYMAZE
Margins and returns on capital
Gross margin83.6%–
Operating margin––
Net margin31.9%–
ROIC35.5%-31.8%
ROE88.6%-38.7%

Balance sheet

LLYMAZE
Balance sheet
Cash$4.9B$390M
Total debt$49.5B$60M
Net debt / EBITDA1.2–
Interest cover38.9×–

Dividends and buybacks

LLYMAZE
Dividends and buybacks
Dividend yield0.5%–
Dividend per share, 12 months$6.34–
Dividend growth a year, past+15.2%over 5 years–
Buyback yield0.3%–
Shareholder yield0.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LLY or MAZE

Didn't find what you were looking for?

Ask us
Which is bigger, Eli Lilly and Company or Maze Therapeutics?

By market value, Eli Lilly and Company ($1.30T) is about 764.6 times Maze Therapeutics ($1.7B), at today's prices.

How did LLY and MAZE stock do over the last 1 years?

Since November 17, 2025, LLY's price moved +35.3% and MAZE's -6.9%. With dividends: LLY +36.2% (+36.2% a year), MAZE -6.9% (-6.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, LLY or MAZE?

The dividend yield at today's price is 0.46% for Eli Lilly and Company and none for Maze Therapeutics. Over the last twelve months they paid $6.34 and – per share.

Which is the better investment, Eli Lilly and Company or Maze Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.